Table 3 Effect of case:control status, treatment group, and their interaction (case:control status × treatment group) on biomarker concentrations. Cases represent participants with rapid FEV1 decline (≥ 40 mL/year), and controls are participants with stable FEV1 (− 20 mL/year to + 20 mL/year). Treatment group represents the effect of being in the virally suppressed vs untreated HIV groups on biomarker concentrations. All models incorporate sex as a covariate.

From: Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

 

F value

Pr (> F)

Surfactant protein Da

 Case:Control

0.24

0.62

 Treatment group

0.08

0.78

 Interaction

0.00

0.96

Club cell secretory protein

 Case:Control

0.69

0.41

 Treatment group

0.35

0.56

 Interaction

1.72

0.19

Interleukin-6a

 Case:Control

0.47

0.49

 Treatment group

2.54

0.11

 Interaction

0.25

0.62

C-reactive protein

 Case:Control

0.03

0.86

 Treatment group

0.12

0.73

 Interaction

1.34

0.25

Fibrinogena

 Case:Control

2.02

0.16

 Treatment group

0.009

0.92

 Interaction

1.26

0.26

D-Dimera

 Case:Control

0.47

0.49

 Treatment group

6.49

0.01

 Interaction

4.53

0.03

  1. aThese models incorporate a random effect for masterplate based on AIC values.
Back to article page